Skip to main content
. 2018 Apr 12;13(4):e0195909. doi: 10.1371/journal.pone.0195909

Fig 2. pH-dependent binding eliminates the TMDD observed in NOD-SCID mice in the presence of human C5.

Fig 2

NOD/SCID mice (n = 6/group) received a single 100 μg IV dose of mAb +/- human C5. (A) Concentration time profiles for mAb 1 (eculizumab reference sequence) in the absence (■) and presence (□) of human C5; mAb 3 (Y27H_S57H) without (▲) and with (△) C5; and mAb 8 (G31H_Y27H_S57H) without (▼) and with C5 (▽). (B) Corresponding ex vivo classical pathway hemolytic activity in mice receiving mAb 1 (■), mAb 3 (▲) mAb 8 (▼), and human C5 only (●).